Search

Search Constraints

You searched for: Author/Creator Vansteenkiste, Johan

Search Results

33. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Issue 6 (20th February 2023)

34. Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III‐N2 NSCLC after Induction Chemotherapy and Resection. Issue 11 (November 2016)

35. Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III‐N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes. Issue 9 (September 2016)

36. Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer. Issue 2 (February 2015)

37. Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer: Summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop. Issue 2 (February 2015)

38. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Issue 1 (April 2015)

39. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Issue 1 (April 2015)

40. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. Issue 2 (December 2015)